Login
Companies $RZLT
$3.53 -$0.05 (1.4%) After hours
Rezolute, Inc. logo

Rezolute, Inc.

rezolutebio.com

What Do They Do?

Develops an antibody therapy for severe low blood sugar caused by overactive insulin signaling, including congenital and tumor-related forms.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2026 annual report
Latest quarter: Q1 FY2027, the three months to Sep 30, 2026
Net income
▼ −2% (Loss)
vs −$18.2M in Q1 FY2026
  • Nov 13, 2026 upLIFT study met its primary endpoint in preliminary results Preliminary results showed 13 participants met the responder criterion; completed-study results were expected by mid-December 2026.
  • Oct 5, 2026 FDA recommended a pre-BLA meeting before an application for congenital HI The FDA did not determine whether ersodetug is approvable for congenital HI.

A narrower disease focus The earlier report described a therapy for congenital hyperinsulinism and an oral therapy for diabetic macular edema; the latest focuses on ersodetug for congenital and tumor-related hyperinsulinism.

Who Do They Compete With?

Competes with Amylyx Pharmaceuticals, Hanmi Pharmaceuticals, and Zealand Pharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support